clinical trial – Medxy AI

Innovative Combination Therapy in Recurrent Advanced Endometrial Cancer: Insights from the ENDOLA Phase I/II Trial

By MedXY 09/16/2025

The ENDOLA trial explored olaparib with metronomic cyclophosphamide and metformin, demonstrating a favorable safety profile and promising efficacy in heavily pretreated recurrent endometrial cancer patients, highlighting molecular subtype-dependent responses.

Clinical Updates Wellness & Lifestyle

Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial

By MedXY 09/16/2025

This phase II/III study assessed whether adding metformin to standard paclitaxel and carboplatin improved outcomes in advanced and recurrent endometrial cancer. The trial was stopped early due to lack of survival benefit and potential harm, highlighting the need for alternative therapeutic strategies.

Clinical Updates Wellness & Lifestyle

Oral Metformin in Non-Muscle-Invasive Bladder Cancer: Insights from a Phase II Marker Lesion Study

By MedXY 09/15/2025

A phase II trial assessing oral metformin for low-grade non-muscle-invasive bladder cancer (NMIBC) found minimal antitumor activity and no significant mechanistic changes, challenging metformin’s role as an intravesical therapeutic agent in this context.

Clinical Updates Wellness & Lifestyle

Evaluating AI-Enhanced EMG Reporting: Insights from a Randomized Controlled Trial

By MedXY 09/14/2025

An RCT evaluated an AI-assisted framework for electrodiagnostic report interpretation, finding no significant improvement over standard physician reporting but highlighting potential workflow benefits for routine cases.

Clinical Updates Wellness & Lifestyle

Preoperative versus Postoperative Stereotactic Radiation Therapy for Brain Metastases: Safety, Feasibility, and Efficiency Insights from a Phase 3 Randomized Trial

By MedXY 09/13/2025

A phase 3 randomized trial demonstrates that preoperative stereotactic radiation therapy (SRT) for brain metastases offers comparable safety and reduced treatment duration compared to postoperative SRT, potentially improving patient care logistics.

Clinical Updates Wellness & Lifestyle

High-Dose Aumolertinib Demonstrates Promising Efficacy in Untreated EGFR-Mutant NSCLC with Brain Metastases: Insights from the ACHIEVE Phase 2 Trial

By MedXY 09/11/2025

The ACHIEVE Phase 2 trial reveals that high-dose aumolertinib offers significant intracranial and systemic control with a manageable safety profile in patients with untreated EGFR-mutant NSCLC and brain metastases, highlighting its therapeutic potential.

Clinical Updates Wellness & Lifestyle

Transcutaneous Auricular Vagus Nerve Stimulation: A Novel Approach to Managing Postpartum Uterine Contraction Pain after Cesarean Delivery

By MedXY 09/11/2025

A randomized clinical trial shows that transcutaneous auricular vagus nerve stimulation significantly reduces postpartum uterine contraction pain, incisional pain, anxiety, and depression, enhancing recovery and sleep quality in cesarean delivery patients.

Clinical Updates Wellness & Lifestyle

Esketamine Monotherapy for Treatment-Resistant Depression: A New Therapeutic Frontier

By MedXY 09/11/2025

A phase 4 randomized trial demonstrates that esketamine nasal spray monotherapy significantly reduces depressive symptoms in adults with treatment-resistant depression, offering a promising alternative to oral antidepressants.

Clinical Updates Wellness & Lifestyle

Evaluating Intra-Arterial Tenecteplase Post-Thrombectomy in Large Vessel Occlusion Stroke: Safety and Early Efficacy from a Dose-Escalation Randomized Trial

By MedXY 09/11/2025

Adjunctive intra-arterial tenecteplase after successful reperfusion in anterior circulation large vessel occlusion stroke demonstrates an acceptable safety profile at low doses, supporting further investigation into its therapeutic potential.

Clinical Updates Wellness & Lifestyle

Medication Adherence in Hypertension: Insights from the TEAMLET Cluster Randomized Clinical Trial and Related Advances

By MedXY 09/11/2025

TEAMLET trial reveals limited impact of EHR-pharmacy linked interventions on medication adherence in hypertension, highlighting complexity of adherence barriers and the need for multifaceted, patient-centered strategies.